News | March 30, 2026
Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
Subscribe To Our Newsletter & Stay Updated
